This company has been acquired
Surface Oncology Dirección
Dirección controles de criterios 3/4
Surface Oncology's CEO is Rob Ross, appointed in Apr 2021, has a tenure of 2.42 years. total yearly compensation is $1.92M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $89.02K. The average tenure of the management team and the board of directors is 2.4 years and 4.7 years respectively.
Información clave
Rob Ross
Chief Executive Officer (CEO)
US$1.9m
Compensación total
| Porcentaje del salario del CEO | 29.5% |
| Permanencia del CEO | 2.4yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 2.4yrs |
| Promedio de permanencia en la Junta Directiva | 4.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically
Nov 07
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts
Aug 08Surface Oncology GAAP EPS of -$0.46 misses by $0.01
Aug 03Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
May 25News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
May 11Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 23Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Jan 18Is Surface Oncology (NASDAQ:SURF) A Risky Investment?
Nov 11Surface Oncology: Staying The Course
Oct 24Surface Oncology: A Diverse, But Early Pipeline
Jul 13Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
Jun 07Surface Oncology EPS beats by $0.04, beats on revenue
May 05Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like
Mar 15Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 16
Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets
Dec 09What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?
Dec 08Surface Oncology shares rise 13% on Fast Track tag for SRF388
Nov 11Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$93m |
| Mar 31 2023 | n/a | n/a | -US$90m |
| Dec 31 2022 | US$2m | US$568k | -US$64m |
| Sep 30 2022 | n/a | n/a | -US$66m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$57m |
| Dec 31 2021 | US$5m | US$506k | -US$78m |
| Sep 30 2021 | n/a | n/a | US$13m |
| Jun 30 2021 | n/a | n/a | US$17m |
| Mar 31 2021 | n/a | n/a | US$21m |
| Dec 31 2020 | US$1m | US$435k | US$59m |
| Sep 30 2020 | n/a | n/a | -US$24m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$810k | US$400k | -US$55m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$35m |
| Dec 31 2018 | US$880k | US$361k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$15m |
| Mar 31 2018 | n/a | n/a | -US$13m |
| Dec 31 2017 | US$467k | US$329k | -US$45m |
Compensación vs. Mercado: Rob's total compensation ($USD1.92M) is above average for companies of similar size in the US market ($USD763.55K).
Compensación vs. Ingresos: Rob's compensation has been consistent with company performance over the past year.
CEO
Rob Ross (49 yo)
2.4yrs
Permanencia
US$1,924,455
Compensación
Dr. Robert W. Ross, also known as Rob, M.D., is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Independent Director at Xilio Therapeutics, Inc....
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.4yrs | US$1.92m | 0.14% $ 89.0k | |
| Chief Medical Officer | 3.6yrs | US$1.06m | sin datos | |
| CFO & Treasurer | 4.8yrs | sin datos | 0.17% $ 109.1k | |
| Deputy General Counsel & Secretary | less than a year | sin datos | 0.051% $ 33.1k | |
| Chief People Officer | no data | sin datos | sin datos | |
| Senior Vice President of Development Operations | 1.8yrs | sin datos | sin datos |
2.4yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: SURF's management team is considered experienced (2.4 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.4yrs | US$1.92m | 0.14% $ 89.0k | |
| Independent Member of Scientific Advisory Board & Director | 5.6yrs | US$80.57k | 0.075% $ 48.6k | |
| Independent Director | 9.4yrs | US$84.57k | 0% $ 0 | |
| Director | 5.6yrs | US$72.57k | 0.21% $ 138.3k | |
| Member of Scientific Advisory Board | 4.7yrs | sin datos | sin datos | |
| Independent Director | 8.8yrs | US$89.07k | 0% $ 0 | |
| Independent Director | 5.6yrs | US$92.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Chairman & Lead Independent Director | 2.2yrs | US$151.82k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.7yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.7yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.7yrs | sin datos | sin datos |
4.7yrs
Permanencia media
55yo
Promedio de edad
Junta con experiencia: SURF's board of directors are considered experienced (4.7 years average tenure).